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Biological medicines have revolutionized the treatment of a broad spectrum of diseases. In spite of their therapeutic value, the cost
of those products is threatening the sustainability of healthcare systems. Regulators have opened the possibility of developing
lower cost versions of those original biologicals used in humans; the so-called biosimilars. Can a biosimilar of a veterinary
medicine be developed, and how should it be studied? The main objectives are: a) identify and select a biomedicine of veterinary-
use product as a reference medicine for development of a biosimilar candidate, and b) suggest the experimental studies needed to
develop a biosimilar in veterinary medicine.
Biological drugs are produced in living cells. A biosimilar is
a biological medicinal that contains a version of the active
substance of an already authorised original biological
medicine the patent of which has already expired. Any
difference with the original product should not compromise
safety nor efficacy.
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Demonstration of biosimilarity is based on a comprehensive
comparability exercise. It includes analytical structural and
analytical comparability, the cornerstone of biosimilarity,
non-clinical studies, bioequivalence, and studies in patients.
If approved both active substances can be considered
essentially the same, and they may be given via the same
route, the same posology and for at the most the same
indications. The European Medicines Agency lead the
issuance of a regulatory framework, and was followed by
major agencies.
Generics Biosimilars
Source Chemical synthesis Produced in a living system
Molecules
Small and easy to 
characterise 
Often molecules bigger and 
structurally more complex
Authorisation National Centralised by EMA
Drug development 
timeline
2-3 years 6-7 years
Clinical trials
Bioequivalence in 
healthy volunteers
Preclinical and clinical trials 
in patients
Toxicologic studies No Yes
Pharmacovigilance Normal Special
R+D costs 0,6-4 million € 50-150 million €
Introduction
What are biosimilars Advantages and interest of biosimilars
They may prevent supply shortages of biological medicines.
They contribute to National Healthcare Systems sustainability. 
They may contribute to innovation: new drugs are developed to
overcome biosimilar competition, and the resources may be
redistributed to new drugs acquisition.
Lokivetmab (active substance of Cytopoint) is a fully
caninised monoclonal antibody (mAb) of the IgG class
authorised for the treatment of chronic manifestations of
atopic dermatitis in dogs. Being a highly characterised
biopharmaceutical product, approved for the treatment of an
increasing prevalence disease and with a remarkable safety
and efficacy profile, it’s a suitable product as a reference
medicine for the development of a biosimilar candidate.
Biosimilar candidate: lokivetmab
ReferencesConclusions
Physicochemical           
trials
Functional 
in vitro
and/or in 
vivo
Non-
clinical 
toxicity 
studies
Clinical 
studies
In the light of the principles guiding human biosimilars
development, set studies is proposed to demonstrate
biosimilarity between the candidate and lokivetmab.
Lokivetmab biosimilar development
plan may not necessarily include
trials in patients.
A heavy structural and functional
comparability may strongly reduce
the need for a clinical phase.
Lokivetmab is an ideal
candidate from the scientific
and the market perspective to
be used as a reference product
for biosimilars development.
It may rise investors interest.
Table 1. Comparison of development and characteristics between 
generics and biosimilars.  
Development proposal of a biosimilar of lokivetmab
Regulatory framework
Primary structure 
(identical)
HOS compared 
evaluation 
Glycoprofile and 
disulphide bonds
Antigen binding kinetics 
comparison (Biacore) 
and in vitro bioassay
Clinical pharmacokinetics 
and pharmacodynamics 
comparison (models)
Through competition they provide increase access of patients to 
buy them.
